SCHEMBL1127809

SCHEMBL1127809

CC(C)S(=O)(=O)Nc1ccc(N)c(S(N)(=O)=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRPF1 P55201 1/20 0.43
BRD4 O60885 1/20 0.41
KDM1A O60341 2/20 0.39
CA12 O43570 4/20 0.39
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
CA9 Q16790 4/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
CA5A P35218 2/20 0.39
CA7 P43166 2/20 0.39
CA14 Q9ULX7 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
CYP2C9 P11712 1/20 0.39
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
ALDH1A1 P00352 2/20 0.36
PGR P06401 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL392853 0.81 CA12 (0.55) BRPF1CA12CA1CA2CA9
SCHEMBL4094379 0.75 ALDH1A1 (0.50) BRPF1BRD4KDM1ACA12CA1
SCHEMBL21104560 0.74 CA2 (0.63) CA12CA1CA2CA9CA4
SCHEMBL2449973 0.73 KEAP1 (0.48) BRPF1BRD4CA1CA2CA9
SCHEMBL1127306 0.73 SGK1 (0.44) BRPF1BRD4CA12CA1CA2
SCHEMBL2446287 0.71 HTR6 (0.56) BRPF1BRD4KDM1ACA1CA2
SCHEMBL13678086 0.70 BRPF1 (0.49) BRPF1BRD4ALDH1A1
SCHEMBL27629294 0.70 CA2 (0.47) CA12CA1CA2CA9CA4
SCHEMBL1523386 0.70 CA1 (0.45) CA12CA1CA2CA9CA7
SCHEMBL12650084 0.69 CDK1 (0.50) BRPF1BRD4KDM1ACA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2283002-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2011-02-16 EP disclosed
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF BRPF1 2781/4885BRD4 745/4885KDM1A 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.